Company Filing History:
2 out of 151 
1 out of 2,494 
1 out of 1,163 Years Active: 2014-2019
Title: Michel Canavaggio: Innovator in Hemostasis
Introduction
Michel Canavaggio is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of biomedicine, particularly in the area of hemostasis. With a total of two patents to his name, Canavaggio's work focuses on improving treatments for bleeding disorders.
Latest Patents
Canavaggio's latest patents include innovative constructs that enhance the therapeutic efficacy of factor VIIa. His invention, titled "Factor VIIa-polysialic acid conjugates having prolonged in vivo half-life," describes a proteinaceous construct that comprises plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives. This construct is bound to a carbohydrate moiety containing 1-4 sialic acid units, which significantly prolongs the in vivo half-life of the protein in the bloodstream of mammals. The invention also outlines methods for controlling bleeding in mammals with bleeding disorders due to functional defects or deficiencies of FVIIa, FVIII, or FIX, as well as during surgical procedures or trauma.
Career Highlights
Throughout his career, Michel Canavaggio has worked with prominent companies in the biopharmaceutical industry, including Baxalta GmbH and Baxter International Inc. His expertise in the field has allowed him to develop groundbreaking solutions that address critical medical needs.
Collaborations
Canavaggio has collaborated with esteemed colleagues such as Peter Turecek and Juergen Siekmann. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Michel Canavaggio is a distinguished inventor whose work in the field of hemostasis has the potential to transform treatment options for patients with bleeding disorders. His innovative patents and collaborations highlight his commitment to advancing medical science.